Dose Responsive Study of Ringer's Lactate Solution in Prevention of Post-induction Hypotension
NCT ID: NCT05924230
Last Updated: 2023-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2023-04-01
2024-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
OBJECTIVES Primary - To find the optimum preloading dosage of Ringer Lactate to prevent post induction hypotension.
Secondary - To find the predictive incidence of Post-induction hypotension according to age, gender, type of surgery and comorbidities.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
After induction inside the Operating Room, All patients will be monitored continuously using Electrocardiography, pulse oximetry, noninvasive Blood pressure measurement and capnography .
Heart rate, Systolic - Diastolic - Mean blood pressure, Oxygen saturation will be monitored as follows :
1. Baseline parameters - Prior to administration of intravenous Ringer's lactate solution
2. T0 (after administration of intravenous Ringer's lactate solution but prior to induction of anaesthesia),
3. T1-T10 (every minute for first 10 mins after induction of anaesthesia) Our institutional standard practice of induction of Anaesthesia with Fentanyl (2 μg/kg), Propofol (2 mg/kg) and Vecuronium (0.1mg/kg ) will be followed and intubation will be done only after first 10 mins post induction.
Amount of Mephentermine needed to correct hypotension despite RL infusion will also be calculated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RL 10
Patients of this group will receive Ringer's lactate (RL) 10ml/kg
RL 10ml/kg
Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
RL 15
Patients of this group will receive 15ml/kg of Ringer's lactate solution
RL 15ml/kg
Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RL 10ml/kg
Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 1) will receive Ringer's lactate 10ml/kg before induction in the receiving area
RL 15ml/kg
Inferior vena cava collapsibility index of all patients will be calculated by ultrasonography and if it is \>50%, then patients of this group (Group 2) will receive Ringer's lactate 15ml/kg before induction in the receiving area
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tata Main Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abhishek Chatterjee
Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abhishek Chatterjee
Role: PRINCIPAL_INVESTIGATOR
Tata Steel
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abhishek Chatterjee
Jamshedpur, Jharkhand, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Abhishek Chatterjee
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMH/IEC/JUNE/011/2022
Identifier Type: -
Identifier Source: org_study_id